SIGLEC8 and duodenitis: The results of a phase 2 trial using lirentelimab (a monoclonal antibody targeting the eosinophil and mast cell transmembrane protein Siglec8) demonstrated a slightly dysphagia improvement in a subset of patients with eosinophilic gastritis or duodenitis [44].